Halloween Special Recombinant 2019-ncov S Protein Rbd-sd1 (c-6his) Flash Sale: 90% Off [70hRQ3jJ]

Recombinant 2019-nCoV S Protein RBD-SD1

Introducing our cutting-edge recombinant 2019-nCoV S Protein RBD-SD1, a high-purity, recombinant protein designed for research applications. This protein is derived from the spike (S) protein of the novel coronavirus, specifically targeting the receptor-binding domain (RBD). With a C-terminal His-tag for easy purification, this product is a valuable tool for various research and diagnostic purposes.

• High Purity: Our recombinant protein is produced through a robust expression system, ensuring high purity and consistent quality.
• Easy Purification: The C-terminal His-tag facilitates efficient purification, simplifying your research process.

Product Properties and Specifications

Our Recombinant 2019-nCoV S Protein RBD-SD1 is specifically engineered for optimal performance in research settings. It is designed to mimic the natural structure of the S protein, making it a reliable tool for studies involving viral entry mechanisms, antibody production, and vaccine development.

• Protein Source: E. coli expression system
• Concentration: 1 mg/ml in PBS buffer (pH 7.4)
• Storage: Store at -20°C for long-term stability; avoid repeated freeze-thaw cycles.

Practical Uses and Target Audience

The Recombinant 2019-nCoV S Protein RBD-SD1 is an essential component for researchers and pharmaceutical companies working on COVID-19-related research. Its applications span across various areas, including:

• Antibody Development: This protein can be used as an antigen for generating antibodies against the novel coronavirus.
• Vaccine Research: It serves as a critical tool for understanding the immune response and developing effective vaccines.

Whether you are a researcher, a scientist, or part of a pharmaceutical company, our recombinant protein is designed to meet your needs. With its high purity, ease of use, and versatile applications, it is a valuable asset for any research lab focused on combating the COVID-19 pandemic.